Company Monitoring Page for CSL

job ratings for CSL

11/11/22
industry:
Manufacturing
company:
CSL
job rating:
1
cesspool of racist guttertrash
09/19/22
industry:
Biotech/Pharmaceutical
company:
CSL
job rating:
1
toxic

latest headlines for company on cafepharma

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
Reuters
Fri, 10/4/24 - 09:41 am
Tags:
GSK, Sanofi, CSL, vaccines, bird flu
CSL gets $121 mln contract to increase US stockpile for bird flu vaccines to 40 mln doses
Reuters
Wed, 09/25/24 - 10:26 pm
Tags:
CSL, HHS, government contracts, vaccines, bird flu
CSL’s ‘big’ post-heart attack drug fails in Phase III trial
Clinical Trials Arena
Mon, 02/12/24 - 10:20 am
Tags:
CSL, clinical trials, CSL112, myocardial infarction, heart attacks
CSL and Arcturus’ Covid-19 booster found to prolong immunity
Clinical Trials Arena
Tue, 02/6/24 - 09:26 am
Tags:
CSL, Arcturus Therapeutics, clinical trials, sa-mRNA, vaccines, COVID-19
CSL gets top-line boost thanks to a post-pandemic boom in plasma collections
Fierce Pharma
Wed, 08/16/23 - 11:14 pm
Tags:
CSL, COVID-19, plasma, CSL Behring, Vifor Pharma
See which pharma brands are the strongest and fastest-growing in 2023
Medical Marketing and Media
Wed, 07/12/23 - 11:12 pm
Tags:
JNJ, Pfizer, CSL, branding
Q&A: Newly-minted CSL chief executive Paul McKenzie and chief medical officer Bill Mezzanotte
Endpoints
Wed, 03/29/23 - 04:16 pm
Tags:
CSL, MRNA, Pharma CEOs, Paul McKenzie
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Drugs.com
Wed, 03/1/23 - 10:07 am
Tags:
CSL, clinical trials, garadacimab, HAE
First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
BioSpace
Tue, 02/21/23 - 10:00 am
Tags:
CSL, Europe, Hemgenix, gene therapy, hemophilia B
Big pharma’s new year catalysts
EP Vantage
Mon, 12/19/22 - 11:05 am
Tags:
AstraZeneca, Daiichi Sankyo, Pfizer, Roche, CSL, uniQure, Novo Nordisk, Eli Lilly
Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small
Forbes
Mon, 12/5/22 - 10:48 am
Tags:
Hemgenix, gene therapy, hemophilia B, drug pricing, CSL
10 Massachusetts Biopharma Companies Hiring Now
BioSpace
Fri, 12/2/22 - 11:18 am
Tags:
Massachusetts, hirings, AbbVie, Moderna Therapeutics, CSL, Intellia Therapeutics, Schrödinger, Visterra, Alloy Therapeutics, Werewolf Therapeutics, Sherlock Biosciences
A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount
Medical Marketing and Media
Thu, 12/1/22 - 10:34 am
Tags:
CSL, Hemgenix, drug pricing, hemophila B
uniQure, CSL claim first okay for hemophilia B gene therapy
Pharmaphorum
Wed, 11/23/22 - 07:53 am
Tags:
uniQure, CSL, hemophila B, gene therapy, Hemgenix, FDA
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
Thu, 11/3/22 - 11:02 am
Tags:
ICER, drug pricing, gene therapy, Biomarin, CSL, Bluebird Bio, hemophilia
CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
Pharmaphorum
Wed, 11/2/22 - 10:15 am
Tags:
CSL, Arcturus, vaccines, MRNA
CSL takes the wraps off a big new R&D center as it eyes vaccines, cell and gene therapies
Endpoints
Wed, 09/14/22 - 09:32 am
Tags:
CSL, R&D, Germany, vaccines, gene therapy, cell therapy
CSL reports Phase III data for garadacimab to treat hereditary angioedema
Clinical Trials Arena
Thu, 08/18/22 - 12:30 pm
Tags:
CSL, clinical trials, garadacimab, HAE, hereditary angiodema
CSL Launches New Unified Global Brand Identity
BioSpace
Thu, 08/11/22 - 10:45 am
Tags:
CSL, rebranding
After delay, CSL's $11.7B deal for Vifor poised to close next week
Fierce Pharma
Tue, 08/2/22 - 10:39 am
Tags:
M&A, CSL, Vifor, antitrust

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.